Printer Friendly

A comparative study to determine the clinical efficacy of Ramipril versus combination of Ramipril and Telmisartan in reducing microalbuminuria associated with grade 2 hypertension.


Hypertension is a disease that affects about one billion individuals worldwide. It increases the risk for development of cerebral, cardiac, and renal events. (1) Many patients with essential hypertension may present with overt or sub-clinical target organ damage (TOD) involving the heart, kidneys, central nervous system or retina at the time of their initial diagnosis. The assessment of sub-clinical TOD has become the key element in evaluating hypertensive patients. Microalbuminuria (MA) is one of the earliest indications of kidney injury in patients with diabetes mellitus and hypertension and is associated with high incidence of cardiovascular morbidity. (2-7) MA possibly reflects a state of increased renal endothelial permeability and is considered an early marker of diffuse endothelial dysfunction (8-10). Since reducing albuminuria delays the progression of complications, this parameter can be used as a benchmark for measuring the efficacy of therapeutic interventions. (11) Over the last few decades, the Renin Angiotensin system (RAS) has been a drug target of particular interest because of its involvement in cardiovascular and renovascular diseases. The two major classes of drugs that target the RAS are the Angiotensin-converting enzyme (ACE) inhibitors and the selective AT1 receptor blockers (ARBs). (12) Both ACE inhibitors and ARBs are effective antihypertensive agents that have been shown to reduce the risk of cardiovascular and renal events. ACE inhibitors prevent the generation of Angiotensin II from Angiotensin I, while ARBs exert their vasodilatation effect at the receptor level by inhibiting the binding of Angiotensin II to the type I receptors. Ramipril is an ACE inhibitor while Telmisartan is a selective angiotensin receptor blocker. Inhibition of the renin-angiotensin system with angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists is particularly effective at reducing the albumin excretion rate, but whether these classes of drugs are more beneficial in patients with microalbuminuria remains to be determined. (13) The objective of the study was to determine whether Ramipril is an effective drug across a broad range of high-risk patients, or whether the combination of Telmisartan and Ramipril provides a more complete blockage of RAS, and provides greater therapeutic benefits especially in reducing microalbuminuria in hypertensive patients.


This study was performed on 60 patients with essential hypertension having microalbuminuria attending the medical outpatient clinic and those admitted to the medical wards. Proven cases of secondary hypertension, pregnant women and those with diabetes mellitus, ischemic heart disease, renal disease, urinary tract infection, raised serum creatinine and macro proteinuria (albumin excretion more than 300 mg/24 hours), were excluded from the study. Informed consent was obtained from each participant. Each participant was interviewed and examined in detail. The blood pressure of each participant was measured, using the auscultatory method with a standardized calibrated mercury column-type sphygmomanometer and a blood pressure above 140/90 mm Hg was regarded as hypertension. A detailed case record was prepared for each patient on a preformed study sheet. They were thoroughly examined for the presence of any other cause of microalbuminuria or other confounding factor. The study subjects were randomly distributed into two groups-Group A comprised of subjects on Ramipril (5 mg/day) and Group B included the subjects on combination of Ramipril and Telmisartan (5mg and 40 mg/day respectively). Patients were monitored first after one week and then at 2, 4, 8, 12, 16 and 20 weeks. The drugs under trial were given for a period of 20 weeks in both groups. In addition to the routine investigations, the study subjects underwent some special investigations such as Electrocardiogram (ECG), Chest radiography, Computed tomography (CT) of the brain and Echocardiography.

Microalbuminuria was assessed by urine albumin-creatinine ratio (ACR) based on the recommendations of the National Kidney Foundation and the American Diabetic Association. (14) The average ACR value from the three urine samples was determined. Urine albumin was estimated by turbidimetry. 5 ml of first-voided, early morning sample of urine was used. The patients were asked to avoid exercise prior to the urine collection. In women, urine examinations were done during the non-menstrual phase of their cycles. ACR value between 30-300 mg/day was taken as MA. Blood urea, serum creatinine and serum potassium levels were also estimated to assess the functional status of the kidney. Results were tabulated in the form of mean and standard deviation, and analyzed by using student's 't' test and the level of significance were determined as 'p' values.


The data from 60 patients who satisfied the inclusion criteria during the study period were analyzed (Table 1). There were 30 patients (16 male and 14 females) in each study group. The mean age in both groups A and B was 55.57 [+ or -] 6.45 and 58.67 [+ or -] 8.93 year respectively. The baseline levels of microalbuminuria in group A and B were196.73 [+ or -] 54.40 mg/day and 166.83 [+ or -] 63.50 mg/day, respectively. The mean arterial blood pressure of group A was 128.89 [+ or -] 4.87 mm Hg while in group B, it was 129.38 [+ or -] 4.13 mm Hg. The differences in the baseline parameters were not statistically significant (p >0.05) (Table 1).

In the present study, in group A, after treatment with Ramipril (5mg/day) for 20 weeks, (Table 2) there was highly significant (p<0.0001) fall in microalbuminuria (from 196.73 [+ or -] 54.40 to 125.93 [+ or -] 39.72), with mean percentage fall of 36.12% at the end of 20 weeks. These findings were consistent with the findings reported by other studies15"18. There was highly significant (p<0.0001) fall in mean arterial pressure from 128.89 [+ or -] 4.87 to 105.40 [+ or -] 3.39 with mean percentage fall of 18.17 at the end of 20 weeks (Table 2). This effect was independent of the fall of microalbuminuria. The similar fall in mean arterial blood pressure has also been reported by various studies using various ACE inhibitors. (19-21)

During the course of treatment with Ramipril there was a significant (p<0.01) increase in potassium level at the end of 20 weeks. There was 4.29% increase in levels of serum potassium (from 4.03 [+ or -] 0.34 mmol/L to 4.21 [+ or -] 0.49 mmol/L), but none of the patients had levels more than 6.5 mmol/L (hyperkalemia). This increase in serum potassium is consistent with the other reported research studies and this rise could be due to the fact that ACEI by decreasing the synthesis of aldosterone, the main regulator of serum potassium, predispose to the development of hyperkalemia. (20,22) There was highly significant fall in level of serum creatinine (21) but insignificant fall was observed in blood urea level during the course of treatment with Ramipril.

In group B, after treatment for 20 weeks, with combination of Ramipril and Telmisartan, (Table 3) there was highly significant (pO.0001) fall in microalbuminuria (from 166.83 [+ or -] 63.50 to 62.40 [+ or -] 27.75), with a mean percentage fall of 63.19% at the end of 20 weeks.

The fall in microalbuminuria has also been reported to be significant to highly significant by various landmark studies using combination of ACE inhibitors and ARB (19-21). The percentage fall (Table 4) in microalbuminuria in the present study matched with the changes reported by these studies. With use of combination of Ramipril and Telmisartan, there was highly significant (pO.0001) 20.79%percentage fall in mean arterial pressure (from 129.38 [+ or -] 4.13 to 102.47 [+ or -] 3.66) and this effect was independent of the fall in microalbuminuria. The fall in blood pressure has also been reported to be highly significant by various studies using combination of various ACE inhibitors and ARBs. (23) Highly significant increase in the level of serum potassium was also observed at the end of 20 weeks. There was 19.06 % increase in the level of serum potassium but none of the patients had levels more than 6.5mmol/L (hyperkalemia) (22) Significant fall in serum creatinine and blood urea level was also observed during the course of treatment with combination therapy. (21)

As a whole the study was uneventful and none of the patients had serious side effects except for dry cough (8% in group A and 4% in group B), dizziness and headache (2% in both groups A and B). None of the patients had increase in serum potassium to the extent where medication needed to be stopped.

Microalbuminuria is frequently accompanied by hyperfiltration and anticipates a decline in renal function, (24) hypertensive microalbuminuria is characterized by unchanged glomerular filtration rate, reduced renal plasma flow, increased filtration fraction, elevated vascular resistance (25-28) and exhaustion of the renal functional reserve. (29) The ACE inhibitors reduce RAS activation by blocking the conversion of Angiotensin I to Angiotensin II, leading to decreased activation of both AT 1 and AT2 receptors. Angiotensin II type 1 receptors predominantly mediate the pathological effects of Angiotensin II, including vasoconstriction and other mechanisms that raise blood pressure as well as vascular hypertrophy, endothelial dysfunction, atherosclerosis, inflammation, and apoptosis. (30) Angiotensin II type 2 receptors, in contrast, mediate mostly opposing and beneficial effects, promoting anti-proliferation, differentiation, regeneration, anti-inflammation, and apoptosis.

In addition to blocking the conversion of Angiotensin I to Angiotensin II, ACE inhibitors block the enzymatic degradation of bradykinin. Increased levels of bradykinin contribute to the positive effects of ACE inhibitors since activation of B2 receptor leads to release of nitric oxide, with vasodilatory and tissue protective results. In addition, evidence is accumulating that ACE itself can act as a cell-surface receptor and that binding of an ACE inhibitor to the enzyme triggers a signaling cascade that leads ultimately to PGI2 generation and additional vasodilatory effects. (31-33) Many factors affect patients' compliance with therapy, one of which is tolerability of the treatment. The tolerability profile of ACE inhibitors is marked by a considerable incidence of cough, affecting up to 35% of patients 34 The cough occurring with ACE inhibitor therapy is related to increased levels of kinins, and it is the most frequent reason for discontinuation of treatment with an ACE inhibitor. (35) Angiotensin-converting enzyme inhibition has also been associated with angio-oedema, which occurs much less frequently than cough (<1%). However, angio-oedema affecting the respiratory passages can be life-threatening (36)

An additional disadvantage of ACE inhibition is that it reduces activity of the AT2 receptor along with the ATI receptor. The functions of the AT2 receptor are generally opposed to those of the ATI receptor; the AT2 receptor has anti-proliferative, pro-differentiation properties and mediates anti-inflammatory responses. (30) The ARBs block the RAS by antagonizing the binding of Angiotensin II to the AT1 receptor. Because the ARBs are selective for the AT1 receptor, these agents have a greater potential for providing a complete inhibition of the RAS than ACE inhibitors. (37) In addition, ARBs have minimal affinity for the AT2 and thus permit activation of the AT2 receptor by Angiotensin II to proceed unopposed, possibly providing beneficial anti-proliferative and anti-inflammatory effects. It should be noted that the potential clinical significance of AT2 receptor-mediated actions is not universally accepted. (30)

Unlike ACE inhibitors, ARBs have no effects on bradykinin accumulation and do not induce NO and PGI2 via the B2 receptor. The clinical implications of this difference between the ARBs and the ACE inhibitors, aside from the absence of kinin-related cough with ARBs, are not known. (37) The ARBs have been associated with a highly favorable tolerability profile, better than that of any of the other classes of antihypertensive. 38

Combination therapy with different classes of antihypertensive agents having complementary mechanisms of action has been shown in numerous studies to provide greater blood pressure reductions than either agent alone. (39) Although ACE inhibitors and ARBs both target the RAS, their mechanisms of action are complementary and have been shown to lower blood pressure to a greater extent when used in combination. (40,41) Adding an ARB to ACE inhibitor therapy may counter reactivation of angiotensin II and aldosterone escape during ACE inhibitor therapy by specifically blocking the AT1 receptor. (33,42)

Inhibitors of the renin-angiotensin system reduce proteinuria by decreasing the systemic arterial pressure and the intraglomerular filtration pressure and by changing pore size and charge of the glomerular filter (43-46). Combining both drugs might therefore achieve more complete blockage of the renin-angiotensin system.

Proteinuria is not only a predictor of renal outcome, but also acts as a pathogenic factor for the progression of renal disease. Recent data suggest a linear relationship between reduction in urinary protein excretion and protection of renal function. Because proteinuria fulfills many criteria of a reliable surrogate marker, the additional reduction in proteinuria achieved by combining an ARB and an ACE inhibitor may be of direct relevance to the patient's renal prognosis.


The combination of Ramipril and Telmisartan provides superior blood pressure (BP) lowering and target organ protection than Ramipril alone, hence the combination of Ramipril and Telmisartan is a better choice to treat and to prevent the progression of the disease.


(1.) Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet. 2007;370:591-603.

(2.) Hebert LA, Spetie DN, Keane WF. The urgent call of albuminuria/proteinuria. Heeding its significance in early detection of kidney disease. Post grad Med. 2001;110:79-82, 87-8, 93-6.

(3.) Ruilope LM, van Veldhuisen DJ, Ritz E, et al. Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol. 2001;38:1782-87.

(4.) Barratt J, Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ. 2007;177:361-68.

(5.) Sukhija R, Aronow WS, Kakar P, et al. Relation of microalbuminuria and coro-nary artery disease in patients with and without diabetes mellitus. Am J Cardiol. 2006;98:279-81.

(6.) Klausen K, Borch-Johnsen K, FeldtRasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110:32-5.

(7.) Schrader J, Luders S, Kulschewski A, et al. Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study). J Hypertens. 2006;24:541-8.

(8.) Ritz E. Heart and kidney: fatal twins? Am J Med. 2006;119:(Suppl 1):S31-9.

(9.) Tsioufis C, Dimitriadis K, Chatzis D, et al. Relation of microalbuminuria to adipo-nectin and augmente C-reactive protein levels in men with essential hypertension. Am J Cardiol. 2005;96:946-51.

(10.) Cottone S, Mule G, Nardi E, et al. Microalbuminuria and early endothelial activation in essential hypertension. J Hum Hypertens. 2007;21:167-72.

(11.) Lozano JV, Llisterri JL, Aznar J, et al. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant. 2001;16 Suppl 1:85-9.

(12.) Unger T. Targeting cardiovascular protection: the concept of dual renin-angiotensin system control. Medscape J Med. 2008;10Suppl.:S4.

(13.) Palatini P. Microalbuminuria in hypertension. Curr Hypertens Rep. 2003;5(3):208-14.

(14.) American Diabetes Association. Diabetic Nephropathy. Diabetes care. 1998;21(Suppl 1):S50-S53

(15.) Gansevoort RT, de Zeeuw D, de Jang PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the reninangiotensin system? Kidney Int. 1994;45:861-7.

(16.) Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy; an updated meta-analysis. Nephrol Dial Transplant. 1995;10 Suppl 9:39-45.

(17.) Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with Diabetes; a meta regression analysis. Ann Intern Med. 1993;118:129-38.

(18.) Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-62.

(19.) Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440-4

(20.) Luno J, Barrio V, Goicoechea MA, et al. Effects of dual blockade of the reninangiotensin system in primary proteinuric nephropathies. Kidney Int Suppl. 2002;(82):S47-52

(21.) Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? ClinTher. 2007;29(9):1803-24

(22.) Ahuja TS, Freeman Jr. D, Mahnken JD, et al. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol. 2000;20:268-72.

(23.) Pedrinelli R, Dell'Omo G, Di Bello V, et al. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. Journal of human nutrition. J Hum Hypertens. 2002 Feb;16(2):79-89..

(24.) Viberti GC, Hill RD, Jarrett RJ, et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982;1(8287):1430-2.

(25.) Mimran A, Ribstein J, DuCailar G. Is microalbuminuria a marker of early intrarenal vascular dysfunction in essential hypertension? Hypertension. 1994;23(6 Pt 2):1018-21.

(26.) Reid M, Bennett F, Wilks R, Forrester T. Microalbuminuria, renal function and waist:hip ratio in black hypertensive Jamaicans. J Hum Hypertens. 1998; 12(4):221-7.

(27.) 27.Mattei P et al. Microalbuminuria and renal hemodynamics in essential hypertension.Eur J Clin Invest 1997; 27: 755-760

(28.) Pontremoli R, Viazzi F, Martinoli C, et al. Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. Nephrol Dial Transplant. 1999;14(2):360-5.

(29.) Losito A, Fortunati F, Zampi I, et al. Impaired renal functional reserve and albuminuria in essential hypertension. Br Med J (Clin Res Ed). 1988; 296(6636): 1562-4.

(30.) Steckelings UM, Kaschina E, Unger T. The AT2 receptor--a matter of love and hate. Peptides. 2005;26(8):1401-9.

(31.) FlemingI, Kohlstedt K, Busse R. New fACEs to the renin-angiotensin system. Physiology (Bethesda). 2005;20:91-5.

(32.) Kohlstedt K, Busse R, Fleming I. Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells. Hypertension. 2005;45(1):126-32.

(33.) Kohlstedt K, Brandes RP, Muller-Esterl W, et al. Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells. Circ Res. 2004;94(1):60-67.

(34.) Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):169S-173S.

(35.) Ravid D, Lishner M, Lang R, et al. Angiotensin-converting enzyme inhibitors and cough: a prospective evaluation in hypertension and in congestive heart failure. J Clin Pharmacol. 1994;34(11):1116-20.

(36.) Sondhi D, Lippmann M, Murali G. Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large community teaching hospital. Chest. 2004;126(2):400-4.

(37.) Unger T, Jakobsen B, Heroys J, et al. Targeting cardiovascular protection: the concept of dual renin-angiotensin system control. Medscape J Med. 2008;10 Suppl.:S4.

(38.) de la Sierra A. Angiotensin receptor blockers in hypertension and cardiovascular diseases. Cardiovasc Hematol Agents Med Chem. 2006;4(1):67-73.

(39.) White WB. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension. Blood Press Monit. 2008;13(2):123-9.

(40.) Ruilope LM, Aldigier JC, Ponticelli C, et al. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Groupfor the Investigation of Valsartan in Chronic Renal Disease. J Hypertens. 2000;18(1):89-95.

(41.) Mogensen CE, Neldam S, Tikkanen I, et al. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440-4.

(42.) Unger T, Stoppelhaar M. Rationale for double renin-angiotensin-aldosterone system blockade. Am J Cardiol. 2007;100(3A):25J-31J.

(43.) Wilmer WA, Rovin BH, Hebert CJ, et al. Management of glomerular proteinuria: a commentary. J Am Soc Nephrol. 2003;14(12):3217-32.

(44.) Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006;116(2):288-96.

(45.) de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65(6):2309-20.

(46.) Hilgers KF, Mann JF. ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol. 2002;13(4):1100-8.

Sahil Chhabra ([dagger])([dagger]), Namrata Chhabra * ([PSI]), Kuldip S Sodhi **, Sahiba Kukreja ([dagger]), Sarah Chhabra * and Kavish Ramessur *

([dagger])([dagger]) Department of Anesthesiology, University of Louisville, Kentucky, USA

* Department of Biochemistry, SSR Medical College, Mauritius

** M.M.I.M.S. & Research, Mullana, Ambala, Haryana, India

([dagger]) Sri Guru Ram Das Medical College & Research Institute, Amritsar, Punjab, India

(Received 21 September 2012 and accepted 09 December 2012)

([PSI]) Correspondence at: Prof. and Head, Department of Biochemistry, SSR Medical College, Mauritius; Mobile: +230 9358966; Email:namarta28@hotmail. com
Table 1: Base line Characteristics of the subjects under study

Serial   Parameters            Group A
                               Mean     S.D.

l.       Systolic blood        169.87   7.08
         pressure(mm Hg)
2.       Diastolic blo d       108.40   4.28
         pressure(mm Hg)
3.       Mean Arterial blood   128.89   4.87
4.       Microalbuminuria      196.73   54.40
5.       Serum Creatinine      1.07     0.16
6.       Blood urea (mg%)      33.88    9.80
7.       Serum Potassium       4.D3     0.34

Serial   Group B         p-value
         Mean     S.D.

l.       170.67   6.71   >0.05

2.       108.73   4.53   >0.05

3.       129.38   4.13   >0.05

4.       166.83   63.5   >0.05

5.       1.15     0.23   >0.05

6.       35.91    8.44   >0.05
7.       3.89     0.24   >0.05

Table 2: Effect of Ramipril on microalbuminuria,
mean systolic blood pressure, mean diastolic blood
pressure, mean arterial pressure, serum potassium,
serum creatinine and blood urea levels in Group A

Serial    Parameter                       Base Line
No.                                       (Mean [+ or -]SD)

1         Micro Albumin uria(mg/day)      196.73+54.40
2.        Mean Systolic Blood             169.87+7.08
3.        Mean Diastolic blood            108.40+4.28
4.        Mean Arterial Pressure(mmHg)    128.89+4.87
5.        Serum Potassium (m.mol/L)       4.03+0.34
6.        Serum Creatinine(mg/d L)        1.0710.16
7.        Blood urea (mg/dL)              33.88+9.80

Serial    After 20 weeks      p-Value
No.       (Mean [+ or -]SD)

1         125.93+39.72        <0.0001
2.        138.20+5.26         <0.0001
3.        89.00+3.74          <0.0001
4.        105.40+3.39         <0.0001
5.        4.21+0.49           <0.01
6.        1.0010.13           <0.001
7.        32.2216.13          >0.05

Table 3: Effect of combination therapy
(Ramipril and Telmisartan) on microalbuminuria,
mean systolic blood pressure, mean diastolic
blood pressure, mean arterial pressure,
serum potassium, serum creatinine and blood
urea levels in Group B patients

Serial   Parameter               Base Line
No.                              (Mean [+ or -] SD)

1.       Micro                   166.83 [+ or -] 63.70
         A Ibuminuria (mg/day)
2.       Mean Systolic Blood     170.67 [+ or -] 6.71
         Pres su re{mmHg)
3.       Mean Diastolic blood    108.73 [+ or -] 4.S3
         pressu re{mmHg)
A.       Mea n Arterial          129.38 [+ or -] 4.87
         Pressu re{mmHg)
5.       Serum Potassium           3.89 [+ or -] 0.24
6.       Serum                     1.15 [+ or -] 0.23
         Creatinine (mg/dL)
7.       Blood urea (mg/dL)       35.91 [+ or -] 8.44

Serial   After 20 weeks          p-Value
No.      (Mean [+ or -] SD)

1.        62.40 [+ or -] 27.75   <0.0001
2.       135.53 [+ or -] 5.67    <0.0001
3.        85.93 [+ or -] 4.83    <0.0001
A.       102.47 [+ or -] 3.66    <0.0001
5.         4.65 [+ or -] 0.55    <0.01
6.         1.05 [+ or -] 0.17    <0.001
7.        34.75 [+ or -] 8.52    <0.01

Table 4: Comparison of effect of Ramipril
(Group A) and combination therapy-Ramipril
and Telmisartan (Group B) on various
parameters in study subjects after
20 weeks of therapy

Serial    Parameter                 Group A
No.                                 (Mean [+ or -]SD)

1.        Mean % fall in Micro      36.12 [+ or -] 8.31
2.        Mean % fall in Systolic   18.59 [+ or -] 2.62
          Blood Pressure(mmHg)
3.        Mean % fall of            17.82 [+ or -] 3.86
          Diastolic blood
4.        Mean % fal1 of Arterial   18.17 [+ or -] 2.68
5.        M ea n % rise in Serum     4.20 [+ or -] 6.65
          Potassium (mmol/L)
6.        Mean % fall in Serum       6.01 [+ or -] 10.39
          Creatinine(mg/d L)
7.        Mean % fall in Blood       2.50 [+ or -] 12.38
          urea (mg/dL)

Serial    Group B               p-Value
No.       (Mean[+ or -] SD)

1.        63.19 [+ or -] 9.23   <0.0001

2.        20.53 [+ or -] 3.32   <0.05

3.        20.97 [+ or -] 2.96   <0.001

4.        20.79 [+ or -] 2.02   <0.0001

5.        19.06 [+ or -] 8.46   <0.0001

6.         7.14 [+ or -] 8.50   >0.05

7.         3.31 [+ or -] 5.84   >0.05
COPYRIGHT 2013 Dr. Arun Kumar Agnihotri
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Original Work
Author:Chhabra, Sahil; Chhabra, Namrata; Sodhi, Kuldip S.; Kukreja, Sahiba; Chhabra, Sarah; Ramessur, Kavis
Publication:Internet Journal of Medical Update
Article Type:Clinical report
Geographic Code:9INDI
Date:Jul 1, 2013
Previous Article:Effect of levothyroxine therapy on dyslipidemia in hypothyroid patients.
Next Article:Ultrasound review of seven cases of breast tuberculosis.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters